Human Metapneumovirus (hMPV): Systematic Literature Review of Economic and Humanistic Disease Burden in Adults
Author(s)
Christopher Bartlett, Psychology1, Sophie Beale, Operational Research2, Anne Littlewood, History and Literary Studies3, Emma Bishop, Social Psychology3, Rachael McCool, Psychology1, Caroline de Courville, Biological Sciences4, Antonio Robles, PhD5.
1York Health Economics Consortium, York, United Kingdom, 2Hare Research, Malton, United Kingdom, 3York Health Economics Consortium Ltd, York, United Kingdom, 4Sanofi, LYON, France, 5Sanofi Vaccines, Lyon, France.
1York Health Economics Consortium, York, United Kingdom, 2Hare Research, Malton, United Kingdom, 3York Health Economics Consortium Ltd, York, United Kingdom, 4Sanofi, LYON, France, 5Sanofi Vaccines, Lyon, France.
Presentation Documents
OBJECTIVES: Human metapneumovirus (hMPV), from the same family as respiratory syncytial virus (RSV), is a significant cause of acute respiratory infections associated with substantial morbidity, especially in older adults with various health profiles. A systematic literature review (SLR) was conducted to identify economic and humanistic disease burden data in adults.
METHODS: Nine databases were searched, including MEDLINE, Embase and EconLit, to identify economic burden (direct and indirect costs) and humanistic burden data (quality of life (QoL), social and emotional impact, daily functioning) in adults (≥18 years) with hMPV. Two reviewers independently assessed records against eligibility criteria. One reviewer extracted eligible data; a second reviewer checked these. A date limit of 2004 was used.
RESULTS: The SLR included 4 studies. Humanistic burden data were reported in 3 studies. Two publications reported Respiratory Intensity and Impact Questionnaire (RiiQ ) Symptom Scale data from the Hospitalized Acute Respiratory Tract Infection (HARTI) study for patients hospitalised with hMPV across 12 countries. Respiratory and systemic symptoms domain scores following screening (n=88) were 1.18 and 0.85 respectively, falling to 0.29 and 0.28 3 months after discharge (n=69) . EQ-5D visual analog scale scores from HARTI increased from 52.44 following screening (n=88) to 74.88 at 3 months (n=68). One evaluation estimated 2.1 disability adjusted life-years (DALYs) loss per 1,000 patients (>65 years) hospitalised with hMPV. 1 US study reported cost data: total healthcare reimbursement (2019) within 1 year of allogeneic hematopoietic cell transplantation (with hMPV): $561,960 versus no infection: $353,878, p<0.0001 (n=181).
CONCLUSIONS: This SLR, limited by sparse evidence often captured in hospital settings, suggests hMPV is associated with a high cost burden and impact on patient QoL. Patients with hMPV are often reported as a subgroup of, e.g., patients with respiratory infection. For a better understanding of the economic and humanistic burden, future studies should focus on the hMPV population.
METHODS: Nine databases were searched, including MEDLINE, Embase and EconLit, to identify economic burden (direct and indirect costs) and humanistic burden data (quality of life (QoL), social and emotional impact, daily functioning) in adults (≥18 years) with hMPV. Two reviewers independently assessed records against eligibility criteria. One reviewer extracted eligible data; a second reviewer checked these. A date limit of 2004 was used.
RESULTS: The SLR included 4 studies. Humanistic burden data were reported in 3 studies. Two publications reported Respiratory Intensity and Impact Questionnaire (RiiQ ) Symptom Scale data from the Hospitalized Acute Respiratory Tract Infection (HARTI) study for patients hospitalised with hMPV across 12 countries. Respiratory and systemic symptoms domain scores following screening (n=88) were 1.18 and 0.85 respectively, falling to 0.29 and 0.28 3 months after discharge (n=69) . EQ-5D visual analog scale scores from HARTI increased from 52.44 following screening (n=88) to 74.88 at 3 months (n=68). One evaluation estimated 2.1 disability adjusted life-years (DALYs) loss per 1,000 patients (>65 years) hospitalised with hMPV. 1 US study reported cost data: total healthcare reimbursement (2019) within 1 year of allogeneic hematopoietic cell transplantation (with hMPV): $561,960 versus no infection: $353,878, p<0.0001 (n=181).
CONCLUSIONS: This SLR, limited by sparse evidence often captured in hospital settings, suggests hMPV is associated with a high cost burden and impact on patient QoL. Patients with hMPV are often reported as a subgroup of, e.g., patients with respiratory infection. For a better understanding of the economic and humanistic burden, future studies should focus on the hMPV population.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE523
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)